title: Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Stoter
authors.forename: S H
authors.initials: SH
authors.lastname: Goey
authors.forename: D
authors.initials: D
authors.lastname: Batchelor
authors.forename: A M
authors.initials: AM
authors.lastname: Eggermont
authors.forename: C
authors.initials: C
authors.lastname: Lamers
authors.forename: J W
authors.initials: JW
authors.lastname: Gratama
authors.forename: R L
authors.initials: RL
authors.lastname: Bolhuis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008875:Middle Aged
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2